Modality
mAb
MOA
FcRni
Target
TROP-2
Pathway
JAK/STAT
Atopic Derm
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Apr 2026
Phase 1Current
NCT06158168
1,118 pts·Atopic Derm
2022-04→2026-04·Recruiting
1,118 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-055d awayPh2 Data· Atopic Derm
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2026-04-05 · 5d away
Atopic Derm
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06158168 | Phase 1/2 | Atopic Derm | Recruiting | 1118 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 |